Inventiva reports preliminary 2023 fiscal year financial

Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022Cash and cash equivalents at €26.9 million, short-term deposits at €...

Related Keywords

Tianqing ,Zhejiang ,China ,Paris ,France General ,France ,Boston ,Massachusetts ,United States ,Russia ,Ukraine ,New York ,Daix ,Bourgogne ,South Korea ,Japan ,Israel ,French ,Chinese ,Julia Cailleteau ,Pascaline Clerc ,Aude Lepreux ,Sino Biopharm ,Nasdaq ,Market Program ,Health Care Conference ,Products Administration ,Corporate Affairs ,European Investment Bank ,Patricial Bank ,Hepalys Pharma Inc ,Chia Tai Tianqing Pharmaceutical Group Co Ltd ,Brunswick Group ,Data Monitoring Committee ,Exchange Commission ,Suspected Unexpected Serious Adverse Reaction ,Long Island City ,Euronext Paris ,Chief Executive Officer ,Hepalys Pharma ,Data Monitoring ,Investigational New Drug ,Medical Products Administration ,At The Market Program ,Hepalys License ,Informed Consent Form ,Patient First Visit ,Annual Health Care Conference ,Paris Hepatology Conference ,Annual Conference Liver Connect ,Nasdaq Global Market ,Roquet Montegon ,Private Securities Litigation Reform Act ,New Drug Application ,Universal Registration Document ,Des March ,Annual Report ,Half Year Report ,Paris Stock Exchange Iva ,Inventiva ,